TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

37 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

33 studies on the map

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) — Research Site, MobileEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma — Research Site, MontgomeryA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — UAB Lung Health Center, BirminghamA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Research Site, FoleyA Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) — Research Site 13, BakersfieldRandomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment — Research Site, ChandlerDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — GSK Investigational Site, SheffieldDepemokimab Asthma Imaging and Bronchoscopy Sub-Study — GSK Investigational Site, BrooksvilleA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma — GSK Investigational Site, Newport BeachEfficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) — Phoenix Children's Hospital- Site Number : 8400001, PhoenixMulti-Center Clean Air Randomized Controlled Trial in COPD — University of Alabama, Lung Health Center, BirminghamEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Chandler Clinical Research Trials- Site Number : 8400025, ChandlerAzithromycin for Critical Asthma - Pediatrics — Johns Hopkins All Children's Hospital, St. PetersburgA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) — GSK Investigational Site, Loxahatchee GrovesA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) — Research Site 23, NorthridgeA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Research Site, AthensA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma — Research Site, AnchorageA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — GSK Investigational Site, DoralTreatment of Rheumatoid Arthritis With DMARDs: Predictors of Response — University of Nebraska Medical Center, OmahaRA-PRO PRAGMATIC TRIAL — East Alabama Arthritis Center PC, AuburnA Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma — Teva Investigational Site 12087, PhoenixTrial to Determine Effective Aspirin Dose in COPD — Johns Hopkins Bayview Medical Center, BaltimoreA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma — GSK Investigational Site, BirminghamA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) — Research Site, Cullman